

Statement of Advice:

**oestrogens, conjugated, bazedoxifene acetate (Duavive®) 0.45mg /
20mg modified-release tablets (No: 1220/17)**
Merck Sharp & Dohme Limited / Pfizer Limited

09 December 2016

ADVICE: in the absence of a submission from the company

oestrogens, conjugated, bazedoxifene acetate (Duavive®) is not recommended for use within NHS Scotland.

Indication under review: Treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-containing therapy is not appropriate.

The company has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

**Chairman,
Scottish Medicines Consortium**